Enterically coated cystamine, cysteamine and derivatives thereof
AssigneeThe Regents of the University of California
InventorsRanjan Dohil, Jerry Schneider
Life of this patent
Estimating the term…
Abstract
The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
Claims27
A method of administering cysteamine or cystamine, or pharmaceutically acceptable salts thereof, to a patient in need thereof comprising administering to said patient a pharmaceutical composition comprising cysteamine or cystamine, or pharmaceutically acceptable salts thereof, twice per day, wherein the composition increases delivery of cysteamine or cystamine, or pharmaceutically acceptable salts thereof, to the small intestine.
A method of administering cysteamine or cystamine, or pharmaceutically acceptable salts thereof, to a patient in need thereof comprising administering to said patient a pharmaceutical composition comprising an enteric coating that provides increased delivery of cysteamine or cystamine, or pharmaceutically acceptable salts thereof, to the small intestine.
A method of treating a subject suffering from cystinosis, comprising administering to said subject a composition comprising an enterically coated cysteamine or cystamine, or cysteamine or cystamine derivative.
A method of treating a subject suffering from a neurodegenerative disease, comprising administering to said subject a composition comprising an enterically coated cysteamine or cystamine, or cysteamine or cystamine derivative.
A method of treating a subject in need of a hepato-protectant agent, comprising administering to said subject a composition comprising an enterically coated cysteamine or cystamine, or cysteamine or cystamine derivative.
A method of administering cysteamine or cystamine, or pharmaceutically acceptable salts thereof, to a patient in need thereof comprising administering to said patient a pharmaceutical composition comprising cysteamine or cystamine, or pharmaceutically acceptable salts thereof, wherein the composition increases delivery of cysteamine or cystamine, or pharmaceutically acceptable salts thereof, to the small intestine and wherein the frequency of administering is less than four times daily.
A method of administering cysteamine or cystamine, or pharmaceutically acceptable salts thereof, to a patient in need thereof comprising administering to said patient a pharmaceutical composition comprising an enteric coating, wherein said pharmaceutical composition provides an increased time to Cmax compared to a cysteamine or cystamine, or pharmaceutically acceptable salts thereof, that is not enterically formulated.
Dependencies are inferred from the claim text.